Nuvaring

Patient Information Leaflet

Warning! Keep this leaflet! Information on the immediate packaging is in a foreign language.
NuvaRing, (0.120 mg + 0.015 mg)/24 h, vaginal ring
Etonogestrel + Ethinylestradiol
Important information about combined hormonal contraceptives

• When used correctly, they are one of the most reliable reversible methods of contraception.
• They slightly increase the risk of blood clots in veins and arteries, especially during the first year of use or after restarting use following a break of 4 weeks or more.
• Be vigilant and consult a doctor if a woman suspects symptoms of blood clots (see section 2.2 "Warnings and precautions" - BLOOD CLOTS).

Please read this leaflet carefully before using the medicine, as it contains
important information for the patient.

• Keep this leaflet, so that you can read it again if necessary.
• If you have any doubts, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not give it to others. The medicine may harm someone else.
• If any side effects occur in the patient, including any side effects not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Table of contents

1. What NuvaRing is and what it is used for
2. What you need to know before using NuvaRing
3. How to use NuvaRing
4. Possible side effects
5. How to store NuvaRing
6. Contents of the pack and other information

1. What NuvaRing is and what it is used for

NuvaRing is a contraceptive medicine in the form of a vaginal ring that prevents pregnancy. Each vaginal ring contains a small amount of two female sex hormones – etonogestrel and ethinylestradiol. These hormones are slowly released from the ring into the bloodstream. Due to the low dose of hormones released, NuvaRing is classified as a low-dose hormonal contraceptive. Since NuvaRing releases two different hormones, it is also known as a combined hormonal contraceptive.
NuvaRing works in the same way as a combined oral contraceptive pill (combined pill). However, unlike the pill, which must be taken daily, NuvaRing is used continuously for 3 weeks. NuvaRing releases two female sex hormones that suppress the release of eggs from the ovaries. Because eggs are not released, the woman cannot become pregnant.

2. Important information before using NuvaRing

General notes
Before starting NuvaRing, you should read the information about blood clots (thrombosis) in section 2. It is particularly important to be aware of the symptoms of blood clots (see section 2.2 "Warnings and precautions" – BLOOD CLOTS).
This leaflet describes situations in which you should stop using NuvaRing or in which its effectiveness may be reduced. In these situations, you should abstain from sexual intercourse or use an additional non-hormonal contraceptive method, such as a male condom or another mechanical method. Do not use calendar-based methods or body temperature monitoring. These methods may be ineffective because NuvaRing affects changes in body temperature and cervical mucus consistency throughout the month.
NuvaRing, like other hormonal contraceptives, does not protect against infection with the HIV virus (AIDS) or other sexually transmitted diseases.

2.1 When not to use NuvaRing
Do not use NuvaRing if you have any of the conditions listed below. If you have any of these conditions, you must inform your doctor. Your doctor will discuss with you which alternative method of contraception would be more suitable.

• if you currently have (or have ever had) a blood clot in the veins of your legs (deep vein thrombosis), in your lungs (pulmonary embolism), or in other organs;
• if you know you have blood clotting disorders—for example, protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden mutation, or antiphospholipid antibodies;
• if you require surgery or will be immobile for a prolonged period (see section 2.2 "Warnings and precautions" – BLOOD CLOTS);
• if you have had a heart attack or stroke;
• if you have (or have previously had) angina pectoris (a condition causing severe chest pain, which may be the first sign of a heart attack) or transient ischaemic attack (temporary stroke-like symptoms);
• if you have any of the following conditions that may increase the risk of arterial blood clots:
• severe diabetes with blood vessel damage
• very high blood pressure
• very high levels of fats in the blood (cholesterol or triglycerides)
• a condition called hyperhomocysteinemia
• if you currently have or have previously had a type of migraine called "migraine with aura";
• if you currently have or have previously had pancreatitis associated with high levels of fats in the blood;
• if you currently have or have previously had severe liver disease and liver function has not returned to normal;
• if you currently have or have previously had benign or malignant liver tumours;
• if you currently have or have previously had breast or genital organ cancer, or there is suspicion of such cancers;
• if you have unexplained vaginal bleeding;
• if you are allergic to ethinylestradiol or etonogestrel or any of the other ingredients of this medicine (listed in section 6).

If any of the above symptoms occur for the first time during use of NuvaRing, remove the vaginal ring immediately and consult your doctor. During this time, use a non-hormonal contraceptive method.
If you have hepatitis C virus infection and are taking medicines containing ombitasvir, paritaprevir, ritonavir, and dasabuvir or glecaprevir, pibrentasvir, do not use the NuvaRing vaginal therapeutic system (see also section 2.4 "NuvaRing and other medicines").

2.2 Warnings and precautions
When should you contact your doctor?
Seek medical advice immediately if:

• you notice possible symptoms of blood clots, which may indicate that you have a blood clot in your leg (deep vein thrombosis), in your lungs (pulmonary embolism), a heart attack, or a stroke (see below "BLOOD CLOTS"). For a description of the symptoms of these serious adverse effects, see "How to recognize the occurrence of blood clots".

Tell your doctor if you have any of the following conditions.
If any of these symptoms develop or worsen during use of NuvaRing, inform your doctor.

• if breast cancer is currently present or has occurred in close family members;
• if you have epilepsy (see section 2.4 "NuvaRing and other medicines");
• if you have liver disease (e.g. jaundice) or gallbladder disease (e.g. gallstones);
• if you have Crohn's disease or ulcerative colitis (chronic inflammatory bowel diseases);
• if you have systemic lupus erythematosus (a disease affecting the body's natural defence system);
• if you have haemolytic uraemic syndrome (a blood clotting disorder causing kidney failure);
• if you have sickle cell anaemia (an inherited disorder of red blood cells);
• if you have been diagnosed with high levels of fats in the blood (hypertriglyceridaemia) or have a positive family history of this condition. Hypertriglyceridaemia is associated with an increased risk of developing pancreatitis;
• if you require surgery or will be immobile for a prolonged period (see section 2.2 "Warnings and precautions" – BLOOD CLOTS);
• if you have recently given birth, as you are then at increased risk of blood clots. Consult your doctor to find out how soon after delivery you can start using NuvaRing;
• if you have phlebitis (inflammation of veins under the skin);
• if you have varicose veins;
• if you have conditions that first occurred or worsened during pregnancy or previous use of sex hormones (e.g. hearing loss, porphyria [a blood disorder], herpes gestationis [a blistering skin rash during pregnancy], or Sydenham's chorea [a nervous system disorder causing involuntary, violent movements]);
• if you experience symptoms of angioedema such as swelling of the face, tongue, and/or throat and/or difficulty swallowing or urticaria potentially with breathing difficulties. Medicines containing estrogens may cause or worsen symptoms of hereditary or acquired angioedema;
• if you currently have or have previously had chloasma (yellowish-brown pigmentation patches, so-called "pregnancy mask", especially on the face). If such patches occur, avoid excessive sun exposure and ultraviolet radiation;
• if you have conditions that make the use of NuvaRing difficult, such as frequent constipation, uterine prolapse, or pain during intercourse;
• if you experience sudden, frequent need to urinate with a burning sensation and/or pain, and if you cannot locate the vaginal ring inside the vagina. These symptoms may indicate accidental placement of the NuvaRing vaginal ring into the bladder.

BLOOD CLOTS
Using combined hormonal contraceptives such as the NuvaRing vaginal ring is associated with an increased risk of blood clots compared to not using such therapy. In rare cases, a blood clot can block a blood vessel and cause serious complications.
Blood clots can occur:

• in veins (referred to as "venous thrombosis" or "venous thromboembolic disease");
• in arteries (referred to as "arterial thrombosis" or "arterial thromboembolic events").

Recovery after a blood clot is not always complete. In rare cases, the consequences of a blood clot can be permanent or, very rarely, fatal.
Remember that the overall risk of harmful blood clots caused by using NuvaRing is small.

HOW TO RECOGNIZE THE OCCURRENCE OF BLOOD CLOTS
Seek immediate medical advice if you experience any of the following symptoms.
Are you experiencing any of these symptoms? Likely reason:

• swelling of the leg or swelling along a vein in the leg or foot, Deep vein thrombosis especially if accompanied by:
• pain or tenderness in the leg, which may occur only when standing or walking;
• increased warmth in the affected leg;
• change in skin colour of the leg, e.g. paleness, redness, or blueness;
• sudden unexplained shortness of breath or rapid breathing; Pulmonary embolism
• sudden cough without an obvious cause, possibly accompanied by coughing up blood;
• sharp chest pain, which may worsen on deep breathing;
• severe dizziness or lightheadedness;
• rapid or irregular heartbeat;
• severe stomach pain.

If you are unsure, consult your doctor, as some of these symptoms, such as cough or shortness of breath, may be mistaken for milder conditions such as a respiratory tract infection (e.g. cold).
Symptoms most commonly occur in one eye: Retinal vein thrombosis

• sudden loss of vision or (blood clot in the eye)
• painless visual disturbances, which may progress to vision loss;
• chest pain, discomfort, or pressure; Heart attack

pressure, heaviness; feeling of tightness or fullness in the chest, arm, or below the breastbone; sensation of fullness, indigestion, or choking; discomfort in the upper body radiating to the back, jaw, throat, arm, or stomach; sweating, nausea, vomiting, or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeat;
sudden weakness or numbness of the face, hands, or feet, especially on one side of the body; sudden confusion, speech disturbances, or difficulty understanding; sudden vision disturbances in one or both eyes; sudden difficulty walking, dizziness, loss of balance, or coordination; sudden, severe, or prolonged headache without known cause; loss of consciousness or fainting with or without seizures. In some cases, stroke symptoms may be transient with almost immediate and complete recovery; however, immediate medical attention is required, as the patient may be at risk of a subsequent stroke.	Stroke
swelling and slight bluish discoloration of the skin of the legs or arms; severe abdominal pain (acute abdomen).	Blood clots blocking other blood vessels

BLOOD CLOTS IN VEINS
What can happen if blood clots form in veins?

• The use of combined hormonal contraceptives is associated with an increased risk of developing blood clots in veins (venous thrombosis). Although these adverse events are rare, they most commonly occur during the first year of using combined hormonal contraceptives.
• If blood clots form in the veins of the leg or foot, this may lead to the development of deep vein thrombosis.
• If a blood clot travels from the leg and lodges in the lungs, it may cause pulmonary embolism.
• In very rare cases, a clot may form in another organ, such as the eye (retinal vein thrombosis).

When is the risk of developing blood clots in veins the highest?
The risk of developing blood clots in veins is greatest during the first year of using combined hormonal contraceptives for the first time. The risk may also be higher when restarting combined hormonal contraceptives (the same or a different product) after a break of 4 weeks or more.
After the first year, the risk decreases, although it remains higher than in women who do not use combined hormonal contraceptives.
If a woman stops using NuvaRing, the risk of blood clots returns to normal within a few weeks.

What factors influence the risk of developing blood clots in veins?
The risk depends on the individual's natural risk of venous thromboembolic disease and the type of combined hormonal contraceptive used.
The overall risk of developing blood clots in the legs or lungs associated with the use of NuvaRing is low.

• In a year, about 2 out of 10,000 women who do not use combined hormonal contraceptives and who are not pregnant will develop blood clots.
• In a year, about 5–7 out of 10,000 women who use combined hormonal contraceptives containing levonorgestrel, norethisterone, or norgestimate will develop blood clots.
• In a year, about 6 to 12 out of 10,000 women who use combined hormonal contraceptives containing norelgestromin or etonogestrel, such as the NuvaRing vaginal contraceptive ring, will develop blood clots.
• The risk of developing blood clots depends on the individual’s medical history (see “Factors that increase the risk of developing blood clots in veins” below).

	Risk of developing blood clots over a year
Women who are not using combined hormonal pills/patches/vaginal rings and are not pregnant	About 2 in 10,000 women
Women using combined oral contraceptive pills containing levonorgestrel, norethisterone, or norgestimate	About 5-7 in 10,000 women
Women using the NuvaRing vaginal ring system	About 6-12 in 10,000 women

Factors increasing the risk of venous blood clots
The risk of venous blood clots associated with the use of the NuvaRing vaginal ring system is low, but certain factors may increase this risk.
The risk is higher:

• if the patient is overweight (body mass index (BMI) above 30 kg/m²);
• if a close family member of the patient has had blood clots in the legs, lungs, or other organs at a young age (e.g. under 50 years). In such cases, the patient may have inherited clotting disorders;
• if the patient requires surgery, is immobilized for a prolonged period due to injury or illness, or has a leg in a cast. It may be necessary to discontinue use of NuvaRing several weeks before surgery or during immobilization. If the patient must stop using NuvaRing, consult the doctor about when it is safe to resume use;
• with increasing age (particularly over 35 years);
• if the patient has given birth within the last few weeks.

The risk of developing blood clots increases with the number of risk factors present in the patient.
Air travel (>4 hours) may temporarily increase the risk of blood clots, especially if the patient has another risk factor present.
It is important to inform the doctor if any of the listed risk factors apply to the patient, even if uncertain. The doctor may decide to discontinue use of NuvaRing.
Inform the doctor if any of the above conditions change during use of NuvaRing, for example, if a close family member is diagnosed with unexplained thrombosis or if the patient gains significant weight.
ARTERIAL BLOOD CLOTS
What can happen if blood clots form in arteries?
Similar to venous blood clots, arterial clots can lead to serious consequences such as heart attack or stroke.
Factors increasing the risk of arterial blood clots
It is important to emphasize that the risk of heart attack or stroke associated with the use of the NuvaRing vaginal ring system is very low, but may increase:

• with age (over approximately 35 years);
• if the patient smokes. When using a hormonal contraceptive such as the NuvaRing vaginal ring system, it is recommended to stop smoking. If the patient is unable to stop smoking and is over 35 years old, the doctor may recommend using another type of contraception;
• if the patient is overweight;
• if the patient has high blood pressure;
• if a close family member has had a heart attack or stroke at a young age (under 50 years). In such cases, the patient may also be at increased risk of heart attack or stroke;
• if the patient or a close family member has high levels of blood lipids (cholesterol or triglycerides);
• if the patient suffers from migraines, particularly migraines with aura;
• if the patient has heart disease (valve disorder, heart rhythm disorder known as atrial fibrillation);
• if the patient has diabetes.

If the patient has more than one of the above conditions, or if any of them are particularly severe, the risk of arterial blood clots may be further increased.
Inform the doctor if any of the above conditions change during use of the NuvaRing vaginal ring system, for example, if the patient starts smoking, a close family member is diagnosed with unexplained thrombosis, or if the patient gains significant weight.
Tumour diseases
The following information is based on studies using combined oral contraceptives and may also apply to NuvaRing. Data regarding vaginal use of hormonal contraceptives (as with NuvaRing) are limited.
A slightly increased incidence of breast cancer has been observed among women using combined oral contraceptives, although it is not known whether this is caused by the medication. It is possible that breast cancer is detected more frequently in these women because they undergo medical examinations more regularly. The increased incidence of breast cancer gradually decreases after discontinuation of combined oral contraceptives.
Regular breast examinations are very important. If any lump is detected, consult a doctor immediately. Also inform the doctor if a close relative has had or has breast cancer (see section 2.2 "Warnings and precautions").
In rare cases, benign liver tumours have been reported in women using combined oral contraceptives, and very rarely, malignant liver tumours. If unusual, severe abdominal pain occurs, consult the treating doctor.
There are reports that endometrial cancer (cancer of the uterine lining) and ovarian cancer occur less frequently in women using combined oral contraceptives. This may also apply to NuvaRing, but this has not yet been confirmed.
Psychiatric disorders
Some women using hormonal contraceptives, including NuvaRing, have reported depression or low mood. Depression can be severe and may sometimes lead to suicidal thoughts. If mood changes or symptoms of depression occur, contact the doctor as soon as possible for further medical advice.
2.3 Children and adolescents
The safety and efficacy of NuvaRing have not been studied in adolescents under 18 years of age.
2.4 Interaction of NuvaRing with other medicines
Always inform the doctor about any medicines or herbal products currently used by the patient. Also inform any other specialist doctor, dentist, or pharmacist prescribing other medicines that NuvaRing is being used. They may advise using an additional contraceptive method (e.g. male condoms), and if so, for how long, as well as whether adjustment of the other medicine is needed.
Some medicines:

• may affect the blood concentration of NuvaRing;
• may reduce its contraceptive effectiveness;
• may cause unexpected bleeding.

This applies to medicines used in the treatment of:

• epilepsy (e.g. primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate);
• tuberculosis (e.g. rifampicin);
• HIV infection (e.g. ritonavir, nelfinavir, nevirapine, efavirenz);
• hepatitis C virus infection (e.g. boceprevir, telaprevir);
• other infections (e.g. griseofulvin);
• pulmonary arterial hypertension (bosentan);
• depression (St. John's wort).

If the patient is taking medicines or herbal remedies that may reduce the effectiveness of NuvaRing, a mechanical contraceptive method (e.g. male condom) should also be used. Because the effect of another medicine on NuvaRing may persist for up to 28 days after stopping the medicine, additional mechanical contraception is required during this time.
Warning: NuvaRing should not be used with a diaphragm, cervical cap, or female condom.
NuvaRing may affect the action of other medicines such as:

• medicines containing cyclosporine;
• the antiepileptic lamotrigine (this may lead to increased frequency of seizures).

If the patient has hepatitis C virus infection and is taking medicines containing ombitasvir, paritaprevir, ritonavir, and dasabuvir, or glecaprevir, pibrentasvir, the NuvaRing vaginal ring system should not be used, as this may cause increased liver function parameters in blood laboratory tests (increased activity of the liver enzyme AlAT).
Before starting these medicines, the treating doctor will prescribe another type of contraceptive.
Use of the NuvaRing vaginal ring system may be resumed approximately 2 weeks after completion of this treatment. See section 2.1 "When not to use NuvaRing".
Before taking any medicine, consult a doctor or pharmacist.
During use of NuvaRing, tampons may be used. Insert NuvaRing before inserting a tampon. Be careful when removing the tampon to avoid accidentally removing NuvaRing. If NuvaRing falls out, rinse it with cold or lukewarm water and reinsert as soon as possible.
Damage to the vaginal ring system has occurred during use of vaginal products such as lubricants or treatments for infections (see section 3.4 "What to do if the vaginal ring system is damaged"). Use of spermicides or vaginal antifungal medicines does not reduce the contraceptive effectiveness of NuvaRing.
Diagnostic tests
If blood or urine laboratory tests are to be performed, inform the person conducting the test that NuvaRing is being used, as the use of the vaginal ring system may affect the results of certain laboratory tests.
2.5 Pregnancy and breastfeeding
NuvaRing must not be used during pregnancy or if pregnancy is suspected. If the patient becomes pregnant while using NuvaRing, remove the vaginal ring system and contact the doctor immediately.
If the patient wishes to stop using NuvaRing because she wants to become pregnant, refer to section 3.5 "What to do if the patient wants to stop using NuvaRing".
Use of NuvaRing is not recommended during breastfeeding. If the patient wishes to use NuvaRing while breastfeeding, consult the doctor first.
2.6 Driving and operating machinery
NuvaRing does not affect the ability to drive or operate machinery.

3. How to use NuvaRing

The NuvaRing medicine can be inserted and removed by yourself. Your doctor will advise you when to start using the medicine. The NuvaRing vaginal ring should be inserted on the appropriate day of the cycle (see section 3.3 "When to insert the first NuvaRing vaginal ring") and left in place continuously for 3 weeks. You should regularly check that the NuvaRing vaginal ring is in the vagina (for example, before and after sexual intercourse) to ensure contraceptive protection. After 3 weeks, remove the NuvaRing and take a one-week break. Withdrawal bleeding usually occurs during this break.

Do not use certain mechanical contraceptive methods for women, such as a diaphragm, cervical cap, or female condom, while using NuvaRing. These mechanical contraceptive methods should not be used as an additional contraceptive method because NuvaRing may interfere with the correct placement and positioning of an intrauterine device, cervical cap, or female condom. However, you may use a male condom as an additional mechanical contraceptive method.

3.1 Inserting and removing NuvaRing

1. Before inserting the ring, check the expiration date (see section 5 "How to store NuvaRing").
2. Wash your hands before inserting or removing the ring.
3. Choose the most comfortable position for insertion, such as standing with one leg raised, squatting, or lying down.
4. Remove the NuvaRing from its pouch.
5. Holding the ring between your thumb and index finger, compress it and insert it into the vagina (see Figures 1–4). Alternatively, the ring can be inserted using the NuvaRing applicator (which is not included in the NuvaRing packaging). The NuvaRing applicator may not be available in all countries. The correct position of the NuvaRing vaginal ring is one where it is not felt. If the ring causes discomfort, gently adjust its position (e.g., push it slightly deeper into the vagina) until you feel comfortable. The exact position of the ring within the vagina does not affect its contraceptive effectiveness.
6. After 3 weeks, remove the ring from the vagina. This can be done by hooking your index finger under the edge of the ring or grasping it with your index and middle fingers and pulling it out (Figure 5). If you can locate the ring in the vagina but are unable to remove it, contact your doctor.
7. Dispose of the used ring with household waste, preferably in the sealed pouch it originally came in. Do not dispose of NuvaRing in the toilet.

How to insert the NuvaRing vaginal ring:

Figure 1
Remove the ring from the pouch

Figure 2
Compress the ring

Figure 3
Choose the most comfortable position

Figure 4A Figure 4B Figure 4C
Insert the ring into the vagina with one hand (Figure 4A), separating the labia with the other hand if needed. Place it inside the vagina so that it is comfortable (Figure 4B). Leave the ring in the vagina for 3 weeks (Figure 4C).

Figure 5
Remove the ring from the vagina by hooking your index finger under its edge or grasping it with your index and middle fingers and pulling it out.

3.2 Three weeks of use, one-week break

1. The ring must remain in the vagina continuously for 3 weeks, starting from the day of insertion.
2. After 3 weeks, remove the ring on the same day of the week and approximately at the same time as when it was inserted. For example, if the NuvaRing was inserted on a Wednesday at about 10:00 PM, it should be removed on a Wednesday 3 weeks later, also at about 10:00 PM.
3. After removing the ring, take a one-week break. Bleeding may occur during this time. It usually starts 2–3 days after removal.
4. Insert a new ring exactly one week after the break (on the same day of the week and approximately at the same time), even if bleeding is still ongoing. If insertion of the new vaginal ring is delayed by more than 3 hours, contraceptive effectiveness may be reduced. In such a case, follow the instructions in section 3.4 "What to do if the patient forgets to insert a new vaginal ring after the one-week break."

If NuvaRing is used according to the above recommendations, subsequent bleeding will occur every month on approximately the same days of the week.

3.3 When to insert the first NuvaRing vaginal ring

• No hormonal contraceptive was used in the previous cycle
  Insert the NuvaRing on the first day of the natural cycle (i.e., the first day of menstruation). NuvaRing is effective from the moment of insertion. There is no need to use any additional contraceptive methods. You may also start using NuvaRing between days 2 and 5 of menstruation, but in this case, an additional contraceptive method (such as a male condom) must be used for the first 7 days of NuvaRing use. This recommendation applies only when starting NuvaRing for the first time.

• The patient used combined oral contraceptives in the previous month
  Begin using NuvaRing no later than the day following the break from the currently used contraceptive. If the current contraceptive includes inactive (placebo) tablets, start using NuvaRing no later than the day after taking the last inactive tablet. If you are unsure which tablet is inactive, consult your doctor or pharmacist. Do not extend the break from the previous oral contraceptive beyond the recommended period. If you have taken your tablets regularly and are certain you are not pregnant, you may stop taking them on any day and immediately start using NuvaRing.

• The patient used a transdermal system (patch) in the previous month
  Begin using NuvaRing no later than the day following the break from the transdermal system. Do not extend the break from the transdermal system beyond the recommended period. If you have used the transdermal system regularly and are certain you are not pregnant, you may discontinue it on any day and immediately start using NuvaRing.

• The patient used a progestin-only pill (minipill) in the previous month
  You may stop using the progestin-only pill on any day and start using NuvaRing the next day at the same time you usually took the pill. An additional contraceptive method (such as a male condom) must be used for the first 7 days of NuvaRing use.

• The patient used injections, an implant, or an intrauterine system releasing progestogen [IUD] in the previous month
  Begin using NuvaRing on the day of the next scheduled injection or on the day of removal of the implant or intrauterine system releasing progestogen. An additional contraceptive method (such as a male condom) must be used for the first 7 days of NuvaRing use.

• After childbirth
  After childbirth, your doctor may recommend waiting until after the first menstruation before starting NuvaRing. Sometimes, NuvaRing may be started earlier; your doctor will advise you when. If you are breastfeeding and wish to use NuvaRing, discuss this with your doctor first.

• After miscarriage
  As advised by your doctor.

3.4 What to do if…

Management in case the ring accidentally falls out of the vagina
The NuvaRing vaginal ring may accidentally fall out of the vagina, for example, if it was inserted incorrectly, during tampon removal, during sexual intercourse, in case of constipation, or uterine prolapse. Therefore, you should regularly check that the ring is in the vagina (for example, before and after sexual intercourse).

Management if the ring has been outside the vagina for some time
The NuvaRing may still protect against pregnancy, depending on how long it was outside the vagina.

If the ring was outside the vagina for:

• less than 3 hours , you are still protected against pregnancy. Wash the vaginal ring with cold or lukewarm (not hot) water and reinsert it as soon as possible, but only if it was outside the vagina for less than 3 hours.
• more than 3 hours during the first or second week of use , contraceptive effectiveness may have decreased. Wash the vaginal ring with cold or lukewarm (not hot) water and reinsert it as soon as possible, and leave it in place continuously for at least 7 days. If you have sexual intercourse during these 7 days, use an additional male condom. If you are in the first week of the cycle and had intercourse in the past 7 days, there is a possibility of pregnancy. In this case, contact your doctor.
• more than 3 hours during the third week of use , contraceptive effectiveness may have decreased. Remove the vaginal ring and choose one of the following two options:
  1 – Insert a new vaginal ring as soon as possible. Inserting a new vaginal ring means starting the next three-week period of use. This may prevent the expected withdrawal bleeding, although mid-cycle bleeding or spotting may occur.
  2 – Do not reinsert a vaginal ring. Wait for withdrawal bleeding to occur and insert a new vaginal ring no later than 7 days after removal or expulsion of the previous one. This approach may only be used if you have used NuvaRing continuously for the past 7 days.
• unknown duration , you may not be protected against pregnancy. Perform a pregnancy test and consult your doctor before inserting a new vaginal ring.

Management in case of damage to the vaginal ring
Very rarely, the NuvaRing may become damaged. Vaginal wall injury has been reported in association with damage to the vaginal ring. If you notice that the NuvaRing is damaged, remove it and insert a new one as soon as possible. Use an additional contraceptive method (e.g., a male condom) for the next 7 days. If you had sexual intercourse before noticing the damage, contact your doctor.

Management if more than one vaginal ring is inserted
There have been no reports of serious harmful effects related to overdose of the hormones in NuvaRing. If more than one vaginal ring is accidentally inserted, nausea, vomiting, or genital bleeding may occur. Remove the additional vaginal ring and contact your doctor if symptoms persist.

Management if the patient forgets to insert a new vaginal ring after the one-week break
If the break in using the vaginal ring was longer than 7 days , insert a new ring as soon as possible. If you have sexual intercourse within the next 7 days, use an additional contraceptive method (e.g., a male condom). If sexual intercourse occurred during the break in using the vaginal ring, there is a possibility of pregnancy. In this case, contact your doctor as soon as possible. The longer the break in using the vaginal ring, the higher the likelihood of pregnancy.

Management if the patient forgets to remove the vaginal ring on time

• If the ring has remained in the vagina longer than 3 weeks but not longer than 4 weeks , you are still protected against pregnancy. Remove the vaginal ring and take a one-week break, then insert a new one.
• If the patient has used the vaginal ring for longer than 4 weeks , there is a possibility of pregnancy. Contact your doctor before inserting a new vaginal ring.

Management if withdrawal bleeding does not occur

• If the patient used NuvaRing according to instructions
  If withdrawal bleeding does not occur on schedule, but the patient used NuvaRing as directed and did not take other medications during this time, the likelihood of pregnancy is very low. Continue using NuvaRing as before. However, if withdrawal bleeding does not occur twice in a row, there is a possibility of pregnancy. Contact your doctor as soon as possible. Do not insert a new NuvaRing until your doctor confirms you are not pregnant.

• If the patient used NuvaRing incorrectly
  If withdrawal bleeding does not occur during the first break in using NuvaRing and the patient used the vaginal ring incorrectly, she may be pregnant. Contact your doctor before using a new NuvaRing.

Management of unexpected bleeding
During use of the vaginal ring, some women may experience unexpected mid-cycle bleeding. You may need sanitary pads. Leave the ring in place and continue using it as before. If irregular bleeding increases or recurs, contact your doctor.

Management if the day of bleeding changes
If NuvaRing is used as directed, menstruation (withdrawal bleeding) will occur during the weekly break in using the vaginal ring. If you wish for withdrawal bleeding to start on a different day, you may shorten the break in using the vaginal ring (but never extend it!).

For example: if withdrawal bleeding usually starts on Friday, and you wish to change it to Tuesday (3 days earlier) next month, insert the new vaginal ring 3 days earlier than usual.

If the break in using the vaginal ring is significantly shortened (e.g., to 3 days or less), withdrawal bleeding may not occur at all during that time. During use of the next vaginal ring, spotting (single drops or stains of blood) or mid-cycle bleeding may occur.

If you are unsure how to proceed, consult your doctor.

Management if you wish to delay the onset of bleeding
Although not recommended, you may delay the onset of menstruation (withdrawal bleeding) by inserting a new vaginal ring immediately after removing the previous one, without taking a break. The new vaginal ring should not be used for longer than 3 weeks. During use of the new vaginal ring, spotting (single drops or stains of blood) or mid-cycle bleeding may occur. To induce withdrawal bleeding, remove the vaginal ring. A regular weekly break between consecutive rings is recommended.

Before deciding to delay menstruation, you may consult your doctor.

3.5 What to do if the patient wishes to stop using NuvaRing
You may stop using NuvaRing at any time.
If you do not wish to become pregnant, consult your doctor about alternative contraceptive methods.
If you stop using NuvaRing because you wish to become pregnant, wait until your first menstruation and then start trying to conceive. This will help determine the due date.

4. Possible adverse effects

Like all medicines, the NuvaRing vaginal ring may cause adverse effects, although not everyone experiences them. If any adverse effects occur, especially severe or persistent ones, or any changes in health that the patient considers related to the use of NuvaRing, medical advice should be sought immediately.

All women using combined hormonal contraceptives have an increased risk of venous blood clots (venous thromboembolic disease) or arterial blood clots (arterial thromboembolic disorders). For detailed information on the various risk factors associated with the use of combined hormonal contraceptives, refer to section 2, "Important information before using NuvaRing".

If there is hypersensitivity (allergy) to any of the ingredients of NuvaRing, this may manifest as (frequency unknown): angioedema and (or) anaphylactic reaction [swelling of the face, lips, tongue, and (or) throat and (or) difficulty swallowing], or urticaria potentially accompanied by breathing difficulties. In such cases, NuvaRing should be removed immediately and medical advice sought without delay (see also section 2.2 "Warnings and precautions").

Adverse effects reported by women using NuvaRing:

Common: may affect up to 1 in 10 women

• Abdominal pain, nausea
• Vaginal yeast infections (such as "thrush"); discomfort due to the presence of the ring in the vagina; genital itching; vaginal discharge
• Headache or migraine headache; depressed mood; decreased libido
• Breast pain; pelvic pain; painful menstruation
• Acne
• Weight gain
• Expulsion of the ring

Uncommon: may affect up to 1 in 100 women

• Vision disturbances; dizziness
• Bloating; vomiting, diarrhoea or constipation
• Feeling of fatigue, malaise or restlessness; mood changes; sudden mood swings
• Oedema (swelling)
• Urinary tract or bladder infections
• Problems or pain during urination; urgency or need to urinate; frequent urination
• Discomfort during intercourse, including pain, bleeding, or discomfort due to the presence of the ring, as perceived by the male partner
• Increased blood pressure
• Increased appetite
• Back pain; muscle cramps; pain in the lower or upper limbs
• Decreased skin sensitivity
• Breast tenderness or enlargement; fibrocystic breast changes (cysts which may cause swelling or breast pain)
• Cervicitis; cervical polyps; cervical ectropion
• Changes in menstrual bleeding (e.g. heavy, prolonged, irregular or complete absence of menstruation); pelvic discomfort; premenstrual syndrome; uterine cramps
• Vaginal infections (fungal or bacterial); burning sensation, unpleasant odour, pain, discomfort or dryness of the vagina or vulva
• Hair loss, rash, itching, skin rash or hot flushes
• Urticaria

Rare: may affect up to 1 in 1,000 women

• Harmful blood clots in a vein or artery, for example:
  • In the leg or foot (e.g. deep vein thrombosis)
  • In the lungs (e.g. pulmonary embolism)
  • Heart attack
  • Stroke
  • Mini-stroke or transient ischaemic attack (TIA)
  • Blood clots in the liver, stomach or intestines, kidneys or eye

The likelihood of developing blood clots may be higher if the patient has any other risk factors (see section 2 for further information on factors increasing the risk of blood clots and symptoms of blood clots).

• Galactorrhoea (discharge of milk from the breast)

Unknown frequency: cannot be estimated from available data

• Chloasma (yellowish-brown pigmented patches on the skin, especially on the face)
• Partner discomfort during intercourse (such as irritation, rash, itching)
• Inability to remove the vaginal ring without medical assistance (e.g. due to adhesion of the vaginal ring to the vaginal wall)
• Vaginal wall injury related to damage of the vaginal ring

Breast cancer and liver tumours have been reported in women using combined hormonal contraceptives. For detailed information, see section 2.2 "Warnings and precautions" – Tumours.

Very rarely, the NuvaRing may become damaged. For additional information, see section 3.4 "Management in case of damage to the vaginal ring".

Reporting of adverse effects

If any adverse effects occur, including those not listed in this leaflet, inform a doctor or pharmacist. Adverse effects can be reported directly to the Department of Monitoring of Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Poland, tel.: +48 22 4921301, fax: +48 22 4921309, website: https://smz.ezdrowie.gov.pl.

Reporting adverse effects helps provide more information on the safety of the medicine.

5. How to store NuvaRing

Keep this medicine out of the sight and reach of children.
Contact a doctor if a child is exposed to the hormones contained in NuvaRing.
Store below 30°C. Keep in the original packaging to protect from light and moisture.
Do not use NuvaRing more than 4 months after the date it was dispensed by the pharmacy. The dispensing date is indicated on the box and on the pouch.
Do not use NuvaRing after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Do not use NuvaRing if you notice any change in colour or any signs of deterioration.
Used vaginal rings should be disposed of in a regular household waste container, preferably in a sealed pouch. Do not flush NuvaRing down the toilet. As with other medicines, unused or expired vaginal rings must not be disposed of via sewage systems or household waste. Ask your pharmacist how to dispose of medicines no longer in use. This will help protect the environment.

6. Contents of the package and other information

What NuvaRing contains

• The active substances are: etonogestrel (11.7 mg) and ethinylestradiol (2.7 mg)
• Other components are: poly(ethylene-vinyl acetate), 28% and 9% vinyl acetate (a type of plastic that does not dissolve in the body), and magnesium stearate.

Etonogestrel and ethinylestradiol are released from the vaginal contraceptive system at a rate of
0.120 mg/day and 0.015 mg/day over a period of 3 weeks.
What NuvaRing looks like and contents of the pack
NuvaRing is a flexible, transparent, colourless or almost colourless ring
with an outer diameter of 54 mm.
Each vaginal contraceptive system is individually packed in a foil pouch. The pouch can be resealed after opening. The pouches are contained in a cardboard box together with the package leaflet. The pack contains 1 or 3 systems.
For further information, please contact the marketing authorisation holder or parallel importer.
Marketing Authorisation Holder in Portugal, country of export:
Organon Portugal, Sociedade Unipessoal, Lda.
Rua Aleksandre Herculano, 50 - Piso 9
1250-011 Lisbon
Portugal
Manufacturer:
N.V. Organon
Kloosterstraat 6
5349 AB Oss
The Netherlands
Parallel Importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Repackaged in:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing Authorisation Number in Portugal, country of export: 3694981
Parallel Import Authorisation Number: 333/24
This medicinal product is authorised for marketing in the European Economic Area and in the United Kingdom (Northern Ireland) under the following name:
NuvaRing
0.120 mg/0.015 mg/24 h, vaginal contraceptive system
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Romania, Poland,
Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom (Northern Ireland).

Package leaflet: Information for the user

Warning! Keep this leaflet! Information on the immediate packaging in a foreign language.
NuvaRing, (0.120 mg + 0.015 mg)/24 h, vaginal contraceptive system
Etonogestrelum + Ethinylestradiolum
Important information about combined hormonal contraceptives

• When used correctly, they are among the most reliable reversible methods of contraception.
• They slightly increase the risk of blood clots in veins and arteries, especially during the first year of use or after restarting use following a break of 4 weeks or more.
• Be vigilant and consult a doctor if you suspect symptoms of blood clots (see section 2.2 "Warnings and precautions" - BLOOD CLOTS).

Please read this leaflet carefully before using the medicine, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any doubts, please consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm someone else.
• If you experience any adverse effects, including any not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Leaflet contents

1. What NuvaRing is and what it is used for
2. Important information before using NuvaRing
3. How to use NuvaRing
4. Possible side effects
5. How to store NuvaRing and the NuvaRing applicator
6. Contents of the package and other information

1. What NuvaRing is and what it is used for

NuvaRing is a contraceptive medicine in the form of a vaginal contraceptive system
that prevents pregnancy. Each vaginal contraceptive system contains a small amount of two
female sex hormones – etonogestrel and ethinylestradiol. These hormones are slowly released
from the system into the bloodstream. Due to the low dose of hormones released, NuvaRing
is classified as a low-dose hormonal contraceptive. Because NuvaRing
releases two different hormones, it is also known as a combined hormonal contraceptive.
NuvaRing works similarly to a combined oral contraceptive pill (combined pill),
but unlike a pill that must be taken daily, NuvaRing is used
continuously for 3 weeks. NuvaRing releases two female sex hormones that suppress
the release of eggs from the ovaries. Since eggs are not released, the user cannot become pregnant.

2. Important information before using NuvaRing

General notes
Before starting NuvaRing, read the information about
blood clots (thrombosis) in section 2. It is especially important to be aware of the symptoms
of blood clots (see section 2.2 "Warnings and precautions" - BLOOD CLOTS).
This leaflet describes situations in which you should stop using NuvaRing or when its effectiveness may be reduced. In these situations, you should abstain from sexual intercourse or use an additional non-hormonal contraceptive method, such as a male condom or another mechanical method. Do not use calendar-based methods or body temperature monitoring. These may be ineffective because NuvaRing affects body temperature changes and cervical mucus consistency throughout the month.
NuvaRing, like other hormonal contraceptives, does not protect against
HIV (AIDS) infection or other sexually transmitted diseases.

2.1 When not to use NuvaRing

Do not use NuvaRing if you have any of the conditions listed below. If you have any of the conditions listed below, inform your doctor. Your doctor will discuss with you which alternative contraceptive method may be more suitable.

• if you currently have (or have ever had) a blood clot in the veins of the legs (deep vein thrombosis), in the lungs (pulmonary embolism), or in other organs;
• if you know you have blood clotting disorders – for example, protein C deficiency, protein S deficiency, antithrombin III deficiency, factor V Leiden mutation, or antiphospholipid antibodies;
• if you are undergoing surgery or will be immobile for a prolonged period (see section 2.2. "BLOOD CLOTS");
• if you have had a heart attack or stroke;
• if you have (or have previously had) angina pectoris (a condition causing severe chest pain, which may be the first sign of a heart attack) or transient ischaemic attack (temporary stroke-like symptoms);
• if you have any of the following conditions, which may increase the risk of arterial blood clots:
• severe diabetes with blood vessel damage
• very high blood pressure
• very high levels of fats in the blood (cholesterol or triglycerides)
• a condition called hyperhomocysteinemia
• if you currently have (or have previously had) a type of migraine called "migraine with aura";
• if you currently have or have previously had pancreatitis associated with high levels of fats in the blood;
• if you currently have or have previously had severe liver disease and liver function has not returned to normal;
• if you currently have or have previously had a benign or malignant liver tumour;
• if you currently have or have previously had breast cancer or genital organ cancer, or if such cancers are suspected;
• if you have unexplained vaginal bleeding;
• if you are allergic to ethinylestradiol or etonogestrel or any of the other ingredients of this medicine (listed in section 6).

If any of the above conditions occur for the first time during use of NuvaRing,
remove the system from the vagina immediately and consult your doctor, and use a non-hormonal contraceptive method in the meantime.
If you have hepatitis C virus infection and are taking medicines containing ombitasvir, paritaprevir, ritonavir and dasabuvir or glecaprevir, pibrentasvir, do not use the NuvaRing vaginal contraceptive system (see also section 2.4 "NuvaRing and other medicines").

2.2 Warnings and precautions

When should you contact your doctor?
Seek immediate medical advice

• if you notice possible symptoms of blood clots, which may indicate that you have blood clots in the leg (deep vein thrombosis), in the lungs (pulmonary embolism), a heart attack, or a stroke (see section below 2.2 "Warnings and precautions" - BLOOD CLOTS). For a description of symptoms of these serious adverse effects, see "How to recognise blood clots".

Tell your doctor if you have any of the following conditions.
If these symptoms appear or worsen during use of NuvaRing, inform your doctor.

• if breast cancer is currently present or has occurred in close family members;
• if you have epilepsy (see section 2.4 "NuvaRing and other medicines");
• if you have liver disease (e.g. jaundice) or gallbladder disease (e.g. gallstones);
• if you have Crohn's disease or ulcerative colitis (chronic inflammatory bowel diseases);
• if you have systemic lupus erythematosus (a disease affecting the body's natural defence system);
• if you have haemolytic uraemic syndrome (a blood clotting disorder causing kidney failure);
• if you have sickle cell anaemia (an inherited disorder of red blood cells);
• if you have high levels of fats in the blood (hypertriglyceridaemia) or a positive family history of this condition. Hypertriglyceridaemia is associated with an increased risk of pancreatitis;
• if you are undergoing surgery or will be immobile for a prolonged period (see below - BLOOD CLOTS);
• if you have recently given birth, as you are at increased risk of blood clots. Consult your doctor for advice on how soon after delivery you can start using NuvaRing;
• if you have phlebitis (inflammation of veins under the skin);
• if you have varicose veins;
• if you have conditions that first occurred or worsened during pregnancy or previous use of sex hormones (e.g. hearing loss, porphyria [a blood disorder], herpes gestationis [a blistering skin rash during pregnancy], or Sydenham's chorea [a nervous system disorder causing involuntary, sudden movements]);
• seek immediate medical advice if you experience symptoms of angioedema such as swelling of the face, tongue, and/or throat and/or difficulty swallowing or if you develop hives with breathing difficulties. Medicines containing estrogens may cause or worsen symptoms of hereditary or acquired angioedema;
• if you currently have or have previously had chloasma (yellowish-brown pigmentation, known as "pregnancy mask", especially on the face). If chloasma occurs, avoid excessive sun exposure and ultraviolet radiation;
• if you have conditions that make using NuvaRing difficult, such as frequent constipation, uterine prolapse, or pain during intercourse;
• if you experience sudden, frequent urge to urinate with a burning sensation and/or pain, and if you cannot locate the vaginal contraceptive system inside the vagina. These symptoms may indicate accidental placement of the NuvaRing vaginal contraceptive system into the urinary bladder.

BLOOD CLOTS
Using combined hormonal contraceptives, such as the NuvaRing vaginal contraceptive system,
is associated with an increased risk of blood clots compared to not using hormonal contraception. In rare cases, a blood clot can block a blood vessel and cause serious complications.
Blood clots may occur:

• in veins (referred to as "venous thromboembolism" or "venous thrombosis");
• in arteries (referred to as "arterial thrombosis" or "arterial thromboembolic events").

Recovery from a blood clot is not always complete. In rare cases, the consequences of a blood clot may be permanent or, very rarely, fatal.
Remember that the overall risk of harmful blood clots caused by using NuvaRing is low.
HOW TO RECOGNISE BLOOD CLOTS
Seek immediate medical advice if you experience any of the following symptoms.
Are you experiencing any of these symptoms? What might be the likely cause?

• swelling of the leg or swelling along a vein in the leg or foot, Deep vein thrombosis especially if accompanied by:
• pain or tenderness in the leg, which may occur only when standing or walking;
• increased warmth in the affected leg;
• change in skin colour of the leg, e.g. pallor, redness, or blueness;
• sudden unexplained shortness of breath or rapid breathing; Pulmonary embolism
• sudden cough without an obvious cause, which may be accompanied by coughing up blood;
• sharp chest pain, which may worsen on deep breathing;
• severe dizziness or lightheadedness;
• rapid or irregular heartbeat;
• severe stomach pain.

If you are unsure, consult your doctor,
as some of these symptoms, such as cough or
shortness of breath, may be mistaken for milder
conditions such as respiratory tract infection (e.g.
common cold).
Symptoms usually affect one eye: Retinal vein thrombosis

• sudden loss of vision or (blood clot in the eye)
• painless visual disturbances, which may progress to vision loss;

chest pain, discomfort, pressure, heaviness; feeling of squeezing or fullness in the chest, arm, or below the breastbone; sensation of fullness, indigestion, or choking; discomfort in the upper body radiating to the back, jaw, throat, arm, or stomach; sweating, nausea, vomiting, or dizziness; extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeat;	Heart attack
sudden weakness or numbness of the face, arms, or legs, especially on one side of the body; sudden confusion, speech disturbances, or difficulty understanding speech; sudden vision disturbances in one or both eyes; sudden difficulty walking, dizziness, loss of balance or coordination; sudden, severe, or prolonged headache without known cause; loss of consciousness or fainting with or without seizures. In some cases, stroke symptoms may be transient with almost immediate and complete recovery; however, medical attention should be sought immediately, as the patient may be at risk of a subsequent stroke.	Stroke
swelling and slightly bluish discoloration of the skin of the legs or arms; severe abdominal pain (acute abdomen).	Blood clots blocking other blood vessels

BLOOD CLOTS IN VEINS
What can happen if blood clots form in veins?

• Use of combined hormonal contraceptives is associated with an increased risk of venous blood clots (venous thromboembolism). Although these adverse events are rare, they most commonly occur during the first year of using combined hormonal contraceptives.
• If blood clots form in the veins of the leg or foot, this may lead to the development of deep vein thrombosis.
• If a blood clot travels from the leg and lodges in the lungs, it may cause pulmonary embolism.
• In very rare cases, a clot may form in another organ, such as the eye (retinal vein thrombosis).

When is the risk of venous blood clots highest?
The risk of developing venous blood clots is greatest during the first year of first-time use of combined hormonal contraceptives. The risk may also be higher when restarting combined hormonal contraceptives (the same or a different product) after a break of 4 weeks or more.
After the first year, the risk decreases, although it remains higher than when not using combined hormonal contraceptives.
If a woman stops using NuvaRing, the risk of blood clots returns to normal within a few weeks.

What factors influence the risk of blood clots?
The risk depends on a woman’s natural risk of venous thromboembolic disease and the type of combined hormonal contraceptive used.
The overall risk of blood clots in the legs or lungs associated with using NuvaRing is small.

• In one year, about 2 out of 10,000 women who do not use combined hormonal contraceptives and are not pregnant will develop blood clots.
• In one year, about 5–7 out of 10,000 women who use combined hormonal contraceptives containing levonorgestrel, norethisterone, or norgestimate will develop blood clots.
• In one year, about 6 to 12 out of 10,000 women who use combined hormonal contraceptives containing norelgestromin or etonogestrel, such as the NuvaRing vaginal system, will develop blood clots.
• The risk of blood clots depends on the individual medical history of the woman (see “Factors increasing the risk of blood clots” below).

Risk of developing
blood clots within one year
Women who do not use combined hormonal contraceptives Approximately 2 out of 10,000 women
and are not pregnant
Women using combined hormonal contraceptive pills Approximately 5–7 out of 10,000 women
containing levonorgestrel, norethisterone, or norgestimate
Women using the NuvaRing vaginal system Approximately 6–12 out of 10,000 women

Factors increasing the risk of venous blood clots
The risk of blood clots associated with using the NuvaRing vaginal system is small, but certain factors may increase this risk.
The risk is higher:

• if the woman has a high body weight (body mass index (BMI) above 30 kg/m²);
• if a close family member has had blood clots in the legs, lungs, or other organs at a young age (e.g., under 50 years). In this case, the woman may have an inherited blood clotting disorder;
• if the woman needs surgery, will be immobile for a prolonged period due to injury or illness, or has a leg in a cast. It may be necessary to stop using NuvaRing several weeks before surgery or immobilization. If the woman must stop using NuvaRing, she should consult her doctor about when she can resume use;
• with increasing age (especially over 35 years);
• if the woman has recently given birth (within the past few weeks).

The risk of blood clots increases with the number of risk factors present in the woman.
Air travel (>4 hours) may temporarily increase the risk of blood clots, especially if the woman has another risk factor.
It is important to inform the doctor if any of these factors apply, even if uncertain. The doctor may decide to discontinue use of NuvaRing.
The woman should inform her doctor if any of the above conditions change during use of NuvaRing, for example, if a close family member is diagnosed with thrombosis of unknown cause or if she gains significant weight.

BLOOD CLOTS IN ARTERIES
What can happen if blood clots form in arteries?
As with venous blood clots, arterial blood clots may cause serious consequences, such as heart attack or stroke.

Factors increasing the risk of arterial blood clots
It is important to emphasize that the risk of heart attack or stroke associated with using the NuvaRing vaginal system is very small, but may increase:

• with age (over approximately 35 years);
• if the woman smokes. While using a hormonal contraceptive such as the NuvaRing vaginal system, it is recommended to stop smoking. If the woman is unable to stop smoking and is over 35 years old, her doctor may recommend using another type of contraception;
• if the woman has a high body weight;
• if the woman has high blood pressure;
• if a close family member has had a heart attack or stroke at a young age (under 50 years). In this case, the woman may also be at increased risk of heart attack or stroke;
• if the woman or a close family member has high levels of fats in the blood (cholesterol or triglycerides);
• if the woman has migraines, particularly migraines with aura;
• if the woman has heart disease (valve disorder, heart rhythm disorder known as atrial fibrillation);
• if the woman has diabetes.

If the woman has more than one of the above conditions, or if any of them are particularly severe, the risk of blood clots may be further increased.
The woman should inform her doctor if any of the above conditions change during use of the NuvaRing vaginal system, for example, if she starts smoking, a close family member is diagnosed with thrombosis of unknown cause, or if she gains significant weight.

CANCERS
The following information is based on studies of combined oral contraceptives and may also apply to NuvaRing. Data on vaginal delivery of hormonal contraceptives (as with NuvaRing) are limited.

A slightly higher incidence of breast cancer has been observed among women using combined hormonal contraceptives, although it is not known whether this is caused by the medications. It is possible that tumors are detected more frequently in users because these women undergo medical examinations more regularly. The increased incidence of breast cancer gradually decreases after stopping combined hormonal contraceptives.
Regular breast examinations are very important. If any lump is detected, the woman should contact her doctor. She should also inform her doctor if a close relative has or has had breast cancer (see section 2.2 “Warnings and precautions”).

In rare cases, benign liver tumors have been reported in women using combined hormonal contraceptives, and very rarely, malignant liver tumors. If unusual, severe abdominal pain occurs, the woman should contact her doctor.
There are reports that combined hormonal contraceptive use is associated with a lower incidence of endometrial cancer (cancer of the uterine lining) and ovarian cancer. This may also apply to NuvaRing, although this has not yet been confirmed.

PSYCHIATRIC DISORDERS
Some women using hormonal contraceptives, including NuvaRing, have reported depression or low mood. Depression can be severe and may sometimes lead to suicidal thoughts. If mood changes or symptoms of depression occur, the woman should contact her doctor as soon as possible for further medical advice.

2.3 Children and adolescents

The safety and efficacy of NuvaRing have not been studied in adolescents under 18 years of age.

2.4 NuvaRing and other medicines

Always inform the doctor about any medicines or herbal products currently being used. The woman should also inform any other doctor or dentist prescribing other medicines (or a pharmacist) that she is using NuvaRing. They may advise using an additional contraceptive method (e.g., male condoms), how long this should be used, and whether adjustment of the other medicine is needed.
Some medicines:

• may affect the blood concentration of NuvaRing;
• may reduce its contraceptive effectiveness;
• may cause unexpected bleeding.

These include medicines used to treat:

• epilepsy (e.g., primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate);
• tuberculosis (e.g., rifampicin);
• HIV infection (e.g., ritonavir, nelfinavir, nevirapine, efavirenz);
• hepatitis C virus infection (e.g., boceprevir, telaprevir);
• other infections (e.g., griseofulvin);
• pulmonary hypertension (bosentan);
• mood disorders (St. John's wort).

If the woman is taking medicines or herbal products that may reduce the effectiveness of NuvaRing, she should also use a mechanical contraceptive method (e.g., male condoms). Because the effect of another medicine on NuvaRing may persist for up to 28 days after stopping the medicine, additional mechanical contraception should be used during this time.
Note: NuvaRing should not be used with a diaphragm, cervical cap, or female condom.
NuvaRing may affect the action of other medicines such as:

• medicines containing cyclosporine;
• the antiepileptic drug lamotrigine (which may lead to increased frequency of seizures).

If the woman has hepatitis C virus infection and is taking medicines containing ombitasvir, paritaprevir, ritonavir, and dasabuvir or glecaprevir, pibrentasvir, she should not use the NuvaRing vaginal system, as this may cause increased liver function parameters in blood tests (increased liver enzyme AlAT activity).
Before starting these medicines, the doctor will prescribe another type of contraceptive.
Use of the NuvaRing vaginal system can be resumed approximately 2 weeks after completing this treatment. See section 2.1 “When not to use NuvaRing.”
Before taking any medicine, consult a doctor or pharmacist.
Tampons may be used during use of NuvaRing. Insert NuvaRing before inserting a tampon. Be careful when removing the tampon to avoid accidentally removing NuvaRing. If expulsion occurs, rinse the vaginal system with cool or lukewarm water and reinsert as soon as possible.
Damage to the vaginal system has occurred during use of vaginal products such as lubricants or treatments for infections (see section 3.4 “What to do if the vaginal system is damaged”). Use of spermicides or vaginal antifungal medicines does not reduce the contraceptive effectiveness of NuvaRing.

Diagnostic tests
If blood or urine laboratory tests are being performed, the woman should inform the person conducting the test that she is using NuvaRing, as use of the vaginal system may affect the results of certain laboratory tests.

2.5 Pregnancy and breastfeeding

NuvaRing must not be used during pregnancy or if pregnancy is suspected. If the woman becomes pregnant while using NuvaRing, the vaginal system should be removed and the doctor contacted.
If the woman wishes to stop using NuvaRing because she wants to become pregnant, refer to section 3.5 “What to do if the woman wants to stop using NuvaRing.”
Use of NuvaRing is not recommended during breastfeeding. If the woman wishes to use NuvaRing while breastfeeding, she should consult her doctor first.

2.6 Driving and using machines

NuvaRing does not affect the ability to drive or operate machinery.

3. How to use NuvaRing

NuvaRing can be inserted and removed by the woman herself. The doctor will advise when to start using it. The NuvaRing vaginal system should be inserted on the correct day of the cycle (see section 3.3 “When to insert the first NuvaRing vaginal system”) and left in place for 3 consecutive weeks. The woman should regularly check that the NuvaRing vaginal system is in the vagina (e.g., before and after sexual intercourse) to ensure contraceptive protection. After 3 weeks, the system should be removed and a one-week break taken. Withdrawal bleeding usually occurs during this break.
Certain mechanical contraceptive methods for women, such as diaphragm, cervical cap, or female condom, should not be used during NuvaRing use. These methods should not be used as additional mechanical contraception because NuvaRing may interfere with the proper placement and positioning of an intrauterine device, cervical cap, or female condom. However, male condoms may be used as an additional mechanical contraceptive method.

3.1 Inserting and removing NuvaRing

1. Before insertion, check the expiry date (see section 5 “How to store NuvaRing and NuvaRing Applicator”).
2. Wash hands before inserting or removing the system.
3. Choose the most comfortable position for insertion, such as standing with one leg raised, squatting, or lying down.
4. Remove the NuvaRing from the pouch.
5. Holding the system between thumb and forefinger, squeeze it and insert into the vagina (see Figures 1–4). Alternatively, the NuvaRing Applicator may be used to help place the system in the vagina (see: Instructions for the User, below). The correct position is one where the system is not felt. If the system causes discomfort, gently adjust its position (e.g., push it slightly deeper into the vagina) until the woman feels comfortable. The exact position within the vagina does not affect its contraceptive action.
6. After 3 weeks, remove the system from the vagina. This can be done by hooking the index finger under the edge of the system or grasping it with the index and middle fingers and pulling it out (Figure 5). If the woman locates the system in the vagina but cannot remove it, she should contact her doctor.
7. Dispose of the used system with household waste, preferably in the sealed pouch it originally came in. Do not flush NuvaRing down the toilet.

How to insert the NuvaRing vaginal system using fingers only:

Figure 1
Remove NuvaRing from pouch

Figure 2
Squeeze the system

Figure 3
Choose the most comfortable position for insertion

Figure 4A Figure 4B Figure 4C
Insert the system into the vagina with one hand (Figure 4A), spreading the labia with the other hand if needed. Place it inside the vagina where it does not cause discomfort (Figure 4B). Leave the system in place for 3 weeks (Figure 4C).

Figure 5
Remove the system from the vagina by hooking the index finger under its edge or grasping it with the index and middle fingers and pulling it out.

Important information about the NuvaRing Applicator:

1. Optional for use when inserting the NuvaRing vaginal system.
2. DO NOT reuse the applicator; it is intended for single use only.
3. DO NOT share the applicator with others.
4. If the applicator is accidentally dropped, wash it with cold or lukewarm (NOT hot) water.
5. After use, immediately dispose of the applicator in a regular household waste container.
6. Do not flush the applicator down the toilet.

How to insert the NuvaRing vaginal system using the applicator:
1: Preparation

	Wash hands before opening the packaging. Open the packaging ONLY immediately before using the applicator. DO NOT use the applicator if the packaging or its contents are visibly damaged.
	The applicator is intended for use EXCLUSIVELY with the NuvaRing vaginal contraceptive system. Do not use it with other medicinal products.
	Refer to the illustration showing the applicator and its individual parts. A. Plunger B. Handle C. Cylinder D. Hole in the cylinder E. NuvaRing vaginal contraceptive system

2: Positioning the plunger and adopting the correct posture

	Pull the plunger gently all the way out.
	Squeeze the opposite sides of the vaginal therapeutic system together and insert it into the opening of the cylinder.
	Gently push the vaginal therapeutic system into the center of the cylinder. The tip of the vaginal therapeutic system should protrude slightly from the opening of the cylinder.
	Choose the most comfortable position for inserting the vaginal therapeutic system, for example lying down, sitting in a squatting position, or standing with one leg raised.

3: Insertion of the vaginal ring and removal of the applicator

	Hold the applicator by the handle between your thumb and middle finger.
	Gently insert the barrel into the vagina until your fingers (resting on the grip) touch the body. Then, using your index finger, gently press the plunger fully down. During use of the applicator, some women experienced a transient, mild stinging sensation.
	The vaginal delivery system will be expelled from the applicator. Gently remove the applicator.
	Ensure that the vaginal delivery system has NOT remained in the applicator. Dispose of the used applicator in a regular household waste container. DO NOT flush the applicator down the toilet. DO NOT reuse the applicator.

3.2 Three weeks of use, one week break

1. The system must remain in the vagina continuously for three weeks without interruption, starting from the day of insertion.
2. After three weeks, it should be removed on the same day of the week and approximately at the same time as it was inserted. For example, if NuvaRing was inserted on a Wednesday around 10:00 PM, it should be removed on a Wednesday three weeks later, around 10:00 PM.
3. After removal of the system, a one-week break should be taken. During this time, bleeding may occur, usually starting 2–3 days after removal.
4. A new system should be inserted exactly one week after removal (on the same day of the week and approximately at the same time), even if bleeding is still ongoing. If insertion of the new system is delayed by more than 3 hours, contraceptive effectiveness may be reduced. In such a case, follow the instructions in section 3.4, "What to do if the patient forgets to insert a new vaginal therapeutic system after the one-week break."

If NuvaRing is used according to the above recommendations, withdrawal bleeding will typically occur each month around the same days of the week.

3.3 When to insert the first NuvaRing vaginal therapeutic system

• Previously not using hormonal contraception Insert the NuvaRing system on the first day of the natural menstrual cycle (i.e., the first day of menstruation). NuvaRing is effective from the moment of insertion. There is no need to use any additional contraceptive methods. NuvaRing may also be started between day 2 and day 5 of menstruation, but in this case, an additional contraceptive method (such as a male condom) must be used during the first 7 days of NuvaRing use. This recommendation applies only when starting NuvaRing for the first time.
• Previously using combined oral contraceptives Begin NuvaRing no later than the day after the break from the current oral contraceptive. If the current oral contraceptive includes placebo tablets, start NuvaRing no later than the day after taking the last placebo tablet. If in doubt about which tablet is the last active one, consult a doctor or pharmacist. Do not extend the break from the current oral contraceptive beyond the recommended period. If the patient has taken her pills regularly and is certain she is not pregnant, she may stop taking the pills at any time and immediately start using NuvaRing.
• Previously using a transdermal system (patch) Begin NuvaRing no later than the day after the transdermal system is removed. Do not extend the break from the transdermal system beyond the recommended period. If the patient has used the transdermal system regularly and is certain she is not pregnant, she may discontinue the transdermal system at any time and immediately start using NuvaRing.
• Previously using progestogen-only pills (minipills) The minipill may be discontinued at any time, and NuvaRing should be inserted the next day at the same time the minipill was usually taken. An additional contraceptive method (such as a male condom) must be used during the first 7 days of NuvaRing use.
• Previously using injectable contraception, an implant, or a progestogen-releasing intrauterine system [IUD] Begin NuvaRing on the day the next injection is due, or on the day the implant or progestogen-releasing intrauterine system is removed. An additional contraceptive method (such as a male condom) must be used during the first 7 days of NuvaRing use.
• After childbirth After childbirth, the doctor may recommend waiting until the first menstruation before starting NuvaRing. Sometimes NuvaRing may be started earlier; the doctor will advise when. If breastfeeding and considering NuvaRing use, this should first be discussed with a doctor.
• After miscarriage As advised by the doctor.

3.4 What to do if…

Management in case the system accidentally falls out of the vagina
The NuvaRing vaginal therapeutic system may accidentally fall out of the vagina, for example, if inserted incorrectly, during tampon removal, during intercourse, in case of constipation, or uterine prolapse. Therefore, it is recommended to regularly check whether the system is in place (e.g., before and after sexual intercourse).
Management if the system has been outside the vagina for some time
The NuvaRing system may still protect against pregnancy, but this depends on how long it was outside the vagina.
If the system was outside the vagina for:

• less than 3 hours, the patient remains protected against pregnancy. The vaginal therapeutic system should be washed with cold or lukewarm (not hot) water and reinserted as soon as possible.
• more than 3 hours during the first or second week of use, contraceptive effectiveness may have decreased. The vaginal therapeutic system should be washed with cold or lukewarm (not hot) water and reinserted as soon as possible, and left in place continuously for at least 7 days. If intercourse occurs during these 7 days, a male condom should also be used. If the patient is in the first week of the cycle and had intercourse during the last 7 days, there is a possibility of pregnancy. In this case, contact a doctor.
• more than 3 hours during the third week of use, contraceptive effectiveness may have decreased. The vaginal therapeutic system should be removed, and one of the following two options should be chosen:
  1. Insert a new vaginal therapeutic system as soon as possible. Inserting a new system starts the next three-week cycle of use. This may prevent the expected withdrawal bleeding, although mid-cycle bleeding or spotting may occur.
  2. Do not reinsert a vaginal therapeutic system. Wait for withdrawal bleeding to occur and insert a new vaginal therapeutic system no later than 7 days after removal or expulsion of the previous one. This approach may only be used if the patient has used NuvaRing continuously for the last 7 days.
• unknown duration, the woman may not be protected against pregnancy. Before inserting a new vaginal therapeutic system, a pregnancy test should be performed and medical advice sought.

Management in case of damage to the vaginal therapeutic system
Very rarely, the NuvaRing system may become damaged. Vaginal wall injury has been reported in association with damage to the vaginal therapeutic system. If the patient notices that NuvaRing is damaged, it should be removed and a new one inserted as soon as possible. An additional contraceptive method (e.g., male condom) should be used for the next 7 days. If intercourse occurred before the damage was noticed, contact a doctor.
Management in case more than one vaginal therapeutic system is inserted
There have been no reports of serious adverse effects related to overdose of hormones in NuvaRing. If more than one vaginal therapeutic system is accidentally inserted, nausea, vomiting, or genital bleeding may occur. The additional vaginal therapeutic system should be removed, and a doctor should be contacted if symptoms persist.
Management if the patient forgets to insert a new vaginal therapeutic system after the one-week break
If the break in use of the vaginal therapeutic system was longer than 7 days, a new system should be inserted as soon as possible. If intercourse occurs during the next 7 days, an additional contraceptive method (e.g., male condom) should be used. If intercourse occurred during the break in use of the vaginal therapeutic system, pregnancy is possible. In this case, contact a doctor as soon as possible. The longer the break in use, the higher the likelihood of pregnancy.
Management if the patient forgets to remove the vaginal therapeutic system on time

• If the system remained in the vagina longer than 3 weeks but not longer than 4 weeks, the patient remains protected against pregnancy. The vaginal therapeutic system should be removed for one week, then a new one inserted.
• If the patient used the vaginal therapeutic system longer than 4 weeks, there is a risk of pregnancy. Before inserting a new vaginal therapeutic system, contact a doctor.

Management if withdrawal bleeding does not occur

• If the patient used NuvaRing according to instructions If withdrawal bleeding does not occur on time, but the patient used NuvaRing as directed and did not take other medications during this time, the likelihood of pregnancy is very low. Continue using NuvaRing as before. However, if withdrawal bleeding does not occur for two consecutive cycles, pregnancy is possible. Contact a doctor as soon as possible. Do not insert a new NuvaRing system until a doctor confirms the patient is not pregnant.
• If the patient used NuvaRing incorrectly If withdrawal bleeding does not occur during the first break and the patient used the vaginal therapeutic system incorrectly, she may be pregnant. Contact a doctor before using a new NuvaRing.

Management of unexpected bleeding
During use of the vaginal therapeutic system, some women may experience unexpected mid-cycle bleeding. Sanitary pads may be needed. Leave the system in place and continue using it as usual. If irregular bleeding increases or recurs, contact a doctor.
Management if the day of bleeding changes
If NuvaRing is used as directed, menstruation (withdrawal bleeding) will occur during the weekly break. If the patient wishes to shift the day of withdrawal bleeding, she may shorten the break in use (but never extend it!).
For example: if withdrawal bleeding usually starts on Friday, and the patient wants it to start on Tuesday (3 days earlier) next month, she should insert the new vaginal therapeutic system 3 days earlier than usual.
If the break is significantly shortened (e.g., to 3 days or less), withdrawal bleeding may not occur at all. During the next cycle of use, spotting (small drops or stains of blood) or mid-cycle bleeding may occur.
If the patient is unsure what to do, she should consult a doctor.
Management if delaying the onset of bleeding is desired
Although not recommended, menstruation (withdrawal bleeding) can be delayed by inserting a new vaginal therapeutic system immediately after removing the previous one, without a break. The new vaginal therapeutic system should not be used for longer than 3 weeks. During use of the new system, spotting or mid-cycle bleeding may occur. To induce withdrawal bleeding, remove the vaginal therapeutic system. A regular weekly break between systems is recommended.
Before deciding to delay menstruation, the patient may consult her doctor.

3.5 Management if the patient wishes to stop using NuvaRing

NuvaRing may be discontinued at any time.
If the patient does not wish to become pregnant, consult a doctor about alternative contraceptive methods.
If the patient stops using NuvaRing because she wishes to become pregnant, she should wait until after the first menstruation before trying to conceive. This helps determine the expected date of delivery.

4. Possible adverse effects

Like all medicines, the NuvaRing vaginal therapeutic system may cause adverse effects, although not everyone experiences them. If any adverse effects occur, especially severe or persistent ones, or any health changes considered related to NuvaRing use, consult a doctor.
All women using combined hormonal contraceptives have an increased risk of blood clots in veins (venous thromboembolic disease) or arteries (arterial thromboembolic events). For detailed information on various risk factors associated with combined hormonal contraceptives, refer to section 2, "Important information before using NuvaRing."
If allergic (hypersensitivity) reactions to any component of NuvaRing occur, they may manifest as (frequency unknown): angioedema and/or anaphylactic reaction (facial, lip, tongue, and/or throat swelling and/or difficulty swallowing) or urticaria, potentially with breathing difficulties. In such cases, remove NuvaRing and contact a doctor immediately (see also section 2.2, "Warnings and precautions").
Women using NuvaRing have reported the following adverse effects:
Common: may affect up to 1 in 10 women

• abdominal pain, nausea
• vaginal yeast infections (e.g., "thrush"); discomfort due to the presence of the system in the vagina; genital itching; vaginal discharge
• headache or migraine headache; depressive mood; decreased libido
• breast pain; pelvic pain; painful menstruation
• acne
• weight gain
• expulsion of the system

Uncommon: may affect up to 1 in 100 women

• vision disturbances; dizziness
• bloating; vomiting, diarrhea, or constipation
• fatigue, malaise, or restlessness; mood changes; sudden mood swings
• edema
• urinary tract or bladder infections
• difficulty or pain during urination; urgency or need to urinate; frequent urination
• discomfort during intercourse, including pain, bleeding, or discomfort due to the system, felt by the male partner
• increased blood pressure
• increased appetite
• back pain; muscle cramps; pain in lower or upper limbs
• decreased skin sensitivity
• breast tenderness or enlargement; fibrocystic breast disease (cysts that may cause breast swelling or pain)
• cervicitis; cervical polyps; cervical ectropion
• changes in menstrual bleeding (e.g., heavy, prolonged, irregular, or complete absence of menstruation); pelvic discomfort; premenstrual syndrome; uterine cramps
• vaginal infections (fungal or bacterial); burning sensation, unpleasant odor, pain, discomfort, or dryness of the vagina or vulva
• hair loss, rash, itching, skin eruptions, or hot flushes
• urticaria

Rare: may affect up to 1 in 1000 women

• harmful blood clots in veins or arteries, for example:
  o in leg or foot (e.g., deep vein thrombosis)
  o in lungs (e.g., pulmonary embolism)
  o heart attack
  o stroke
  o transient ischemic attack (mini-stroke) or transient stroke-like symptoms
  o blood clots in the liver, stomach, intestine, kidneys, or eye

The risk of blood clots may be higher if the patient has other risk factors (see section 2 for further information on risk factors and symptoms of blood clots).

• galactorrhea (milk-like discharge from the breast)

Unknown frequency: cannot be estimated from available data

• chloasma (yellowish-brown pigmentation spots on the skin, especially on the face)
• partner’s intercourse discomfort (e.g., irritation, rash, itching)
• inability to remove the vaginal therapeutic system without medical assistance (e.g., due to adhesion of the system to the vaginal wall)
• vaginal wall injury related to damage of the vaginal therapeutic system

Breast cancer and liver tumors have been reported in women using combined hormonal contraceptives. For detailed information, see section 2.2, "Warnings and precautions" – Tumors.
Very rarely, NuvaRing may become damaged. For additional information, see section 3.4, "Management in case of damage to the vaginal therapeutic system."
Reporting adverse effects
If any adverse effects occur, including those not listed in this leaflet, inform a doctor or pharmacist. Adverse effects can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl .
Reporting adverse effects helps gather more information on the safety of the medicine.

5. How to store NuvaRing and NuvaRing Applicator

Keep the medicine out of sight and reach of children.
Contact a doctor if a child is exposed to hormones in NuvaRing.
Store below 30°C. Keep in the original packaging to protect from light and moisture.
Do not use NuvaRing more than 4 months after the date it was dispensed by the pharmacy. This date is indicated on the box and on the vaginal therapeutic system pouch.
Do not use NuvaRing after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Do not use NuvaRing if a color change is noticed or if there are any signs of deterioration.
Used vaginal therapeutic systems should be disposed of in a regular household waste container, preferably in a sealed pouch. Used applicators should be disposed of in a regular household waste container. Do not flush NuvaRing or the NuvaRing Applicator down the toilet. Unused or expired medicines, including NuvaRing systems, should not be disposed of via sewers or household waste. Ask a pharmacist how to dispose of medicines no longer in use. This helps protect the environment.

6. Contents of the package and other information

What NuvaRing contains

• Active substances: etonogestrel (11.7 mg) and ethinylestradiol (2.7 mg)
• Other components: poly(ethylene-vinyl acetate), 28% and 9% vinyl acetate (a type of plastic that does not dissolve in the body), and magnesium stearate.

Etonogestrel and ethinylestradiol are released from the vaginal therapeutic system at a rate of 0.120 mg/day and 0.015 mg/day, respectively, over a 3-week period.
What NuvaRing and the NuvaRing Applicator look like and contents of the package
NuvaRing is a flexible, transparent, colorless or almost colorless ring with an outer diameter of 54 mm.
Each vaginal therapeutic system is individually packaged in a foil pouch. The pouch can be resealed after opening.
The applicator is a non-sterile, single-use medical device made of PP plastic. Each applicator is individually packaged. The applicator bears the CE marking, embossed on the medical device.
The pouch(es) containing the vaginal therapeutic system(s) and applicator(s) are placed in a cardboard box with the package leaflet.
Each package contains 1 or 3 systems and applicators.
For more detailed information, contact the responsible entity or parallel importer.
Responsible entity in Portugal, country of export:
Organon Portugal, Sociedade Unipessoal, Lda.
Rua Aleksandre Herculano, 50 - 9th Floor
1250-011 Lisbon
Portugal
Manufacturer:
N.V. Organon
Kloosterstraat 6
5349 AB Oss
The Netherlands
Parallel importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Repackaged in:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Portugal marketing authorization number: 5717756
Parallel import authorization number: 333/24
This medicinal product is authorized for marketing in the European Economic Area and the United Kingdom (Northern Ireland) under the following name:
NuvaRing
0.120 mg / 0.015 mg / 24 h, vaginal therapeutic system
Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Norway, Romania, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, United Kingdom (Northern Ireland).